Paul Finley, MD
Ophthalmology · Hillsboro, ORNPI 1073517660
Payments from drug & device makers
What this record shows
21 manufacturers reported payments, led by Rxsight Inc at 45.5% of the total. Reporting peaked in 2024 at $1,422 and has fallen 68.5% since, to $448 in 2025.
Across 63 payments — averaging $44.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$1K
- Regeneron Healthcare Solutions, Inc.$444
- AbbVie$169
- Alcon$157
- Johnson & Johnson Surgical Vision, Inc.$143
- Sun Pharmaceutical Industries Inc.$94
- plus $507 from 15 others
What the payments were for
- Food & beverage$1,57857%
- Education$1,20043%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 4 | $1,265 |
| Regeneron Healthcare Solutions, Inc. | 14 | $444 |
| AbbVie(2 entities) | 7 | $169 |
| Alcon | 2 | $157 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $143 |
| Sun Pharmaceutical Industries Inc. | 5 | $94 |
| Thea Pharma Inc. | 4 | $67 |
| Amgen(2 entities) | 3 | $63 |
| Mallinckrodt Hospital Products Inc. | 2 | $51 |
| Bausch & Lomb Americas Inc. | 2 | $47 |
| Kala Pharmaceuticals, Inc. | 2 | $42 |
| Novartis | 3 | $42 |
| Aerie Pharmaceuticals, Inc. | 2 | $42 |
| Tarsus Pharmaceuticals, Inc. | 2 | $38 |
| Biotissue Holdings Inc. | 1 | $20 |
| Biogen | 1 | $20 |
| Omeros Corporation | 1 | $19 |
| AstraZeneca | 1 | $17 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| Iridex Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RXSIGHT INJECTOR HANDPIECE$1,200
- RXSIGHT CONTACT LENS$1,200
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$1,200
- LIGHT ADJUSTABLE LENS (LAL)$1,200
- RXSIGHT INJECTOR CARTRIDGE$1,200
- Clareon$144
- EYLEA HD$125
How this compares
$2,778 in reported general payments places this provider in the 75th percentile of 248 ophthalmology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 45 | $34,012 |
| LumiganBimatoprost | 25 | $10,546 |
| Latanoprost | 396 | $4,719 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 25 | $4,588 |
| VyzultaLatanoprostene Bunod | 11 | $3,598 |
| Prednisolone Acetate | 92 | $3,253 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 147 | $2,099 |
| Travoprost | 15 | $1,912 |
| Doxycycline Hyclate | 37 | $1,132 |
| Timolol Maleate | 133 | $995 |
| Brimonidine Tartrate | 60 | $465 |
| ErythromycinErythromycin Base | 32 | $431 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 31 | $377 |
| Dorzolamide Hcl | 13 | $204 |
| Ofloxacin | 13 | $159 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $169 | $44,55770 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $47 | $3,59811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 248 ophthalmology providers in Oregon.
Other ophthalmology in Hillsboro
- Ross PassoHillsboro$3K
- Chad GoinsHillsboro$3K
- David HuangCorvallis$67K
- Mark PennesiPortland$56K
- Rene ChoiPortland$21K
- Balamurali AmbatiEugene$19K
- Richard HoffmanEugene$17K
- Bart AdamsPendleton$17K
- Richard WeleberPortland$14K
- Aazim SiddiquiPortland$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.